| Abstrakt: |
A study conducted by researchers at Sapienza University of Rome aimed to evaluate the rate of major adverse cardiovascular events (MACE) reported during treatment with phosphodiesterase 5 inhibitors (PDE5i) for erectile dysfunction. The study analyzed data from the Eudra-Vigilance (EV) database, which manages and analyzes data on adverse reactions to medicines. The researchers found that PDE5i drugs were infrequently associated with MACE (<5%), but the risk was higher in younger patients, particularly for sildenafil. Clinicians should consider these findings when prescribing PDE5i, especially in young patients. [Extracted from the article] |
